Maribavir

FDA

• Treatment of post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet in adults and pediatric patients (≥12 years of age and weighing at least 35 kg)
  • For any patient to be started on maribavir, use of the Takeda Livtencity PATIENT START FORM is required.